Observational study evaluates salivary S100B as a noninvasive biomarker for predicting TBI outcomes, suggesting its clinical use.
Salivary S100B at 6 hours post-TBI showed superior prognostic performance compared to plasma and earlier saliva samples, highlighting its potential as a noninvasive biomarker for TBI prognosis.
No takes yet. Share an insight, caveat, or question.
Fernandes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: